These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23540847)

  • 1. Efficacy of tetravalent dengue vaccine in Thai schoolchildren - Authors' reply.
    Sabchareon A; Wallace D; Lang J; Bouckenooghe A; Moureau A
    Lancet; 2013 Mar; 381(9872):1094-5. PubMed ID: 23540847
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of tetravalent dengue vaccine in Thai schoolchildren.
    McKibben L
    Lancet; 2013 Mar; 381(9872):1094. PubMed ID: 23540848
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of tetravalent dengue vaccine in Thai schoolchildren.
    Moi ML; Takasaki T; Kurane I
    Lancet; 2013 Mar; 381(9872):1094. PubMed ID: 23540846
    [No Abstract]   [Full Text] [Related]  

  • 4. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
    Sabchareon A; Wallace D; Sirivichayakul C; Limkittikul K; Chanthavanich P; Suvannadabba S; Jiwariyavej V; Dulyachai W; Pengsaa K; Wartel TA; Moureau A; Saville M; Bouckenooghe A; Viviani S; Tornieporth NG; Lang J
    Lancet; 2012 Nov; 380(9853):1559-67. PubMed ID: 22975340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dengue vaccines: implications for dengue control.
    Robinson ML; Durbin AP
    Curr Opin Infect Dis; 2017 Oct; 30(5):449-454. PubMed ID: 28719400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction.
    Plennevaux E; Sabchareon A; Limkittikul K; Chanthavanich P; Sirivichayakul C; Moureau A; Boaz M; Wartel TA; Saville M; Bouckenooghe A
    Vaccine; 2016 May; 34(24):2707-12. PubMed ID: 27102820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.
    Imoto J; Konishi E
    Vaccine; 2007 Jan; 25(6):1076-84. PubMed ID: 17084490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue vaccine efficacy trial: does interference cause failure?
    Swaminathan S; Khanna N; Herring B; Mahalingam S
    Lancet Infect Dis; 2013 Mar; 13(3):191-2. PubMed ID: 23427882
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue vaccine development: a 75% solution?
    Halstead SB
    Lancet; 2012 Nov; 380(9853):1535-6. PubMed ID: 22975339
    [No Abstract]   [Full Text] [Related]  

  • 11. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
    Gessner BD; Wilder-Smith A
    Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An effective dengue vaccine: a glass half full or half empty?
    Arya V
    Natl Med J India; 2013; 26(1):38-9. PubMed ID: 24066994
    [No Abstract]   [Full Text] [Related]  

  • 13. Guidelines for clinical trials of dengue vaccine in endemic areas.
    Hombach J
    J Clin Virol; 2009 Oct; 46 Suppl 2():S7-9. PubMed ID: 19800564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review.
    Agarwal R; Wahid MH; Yausep OE; Angel SH; Lokeswara AW
    Acta Med Indones; 2017 Jan; 49(1):24-33. PubMed ID: 28450651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAGE committee advice on dengue vaccine.
    Pang T
    Lancet Infect Dis; 2016 Aug; 16(8):880-2. PubMed ID: 27477966
    [No Abstract]   [Full Text] [Related]  

  • 16. Dengue vaccine--time to act now.
    Pang T; Thiam DGY; Tantawichien T; Ismail Z; Yoksan S
    Lancet; 2015 May; 385(9979):1725-1726. PubMed ID: 25943934
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Status of vaccine research and development of vaccines for dengue.
    Vannice KS; Durbin A; Hombach J
    Vaccine; 2016 Jun; 34(26):2934-2938. PubMed ID: 26973072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection.
    Pitisuttithum P; Bouckenooghe A
    Expert Rev Vaccines; 2016 Jul; 15(7):795-8. PubMed ID: 27171845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.